SDHB deficiency silences ABCB1 expression and confers therapeutic vulnerability across multiple cancer types
Succinate dehydrogenase B (SDHB)-deficient cancers, including pheochromocytoma and paraganglioma (PPGL), renal cell carcinoma (RCC), and gastrointestinal stromal tumor (GIST), exhibit aggressive clinical behavior with limited treatment options. To identify novel therapeutic vulnerabilities, we performed high-throughput drug screening using co-cultured human SDHB-deficient and SDHB-reconstituted…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
